




The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 8.4% points. The greatest weakness of PUMA Biotechnology INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 183% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 116% points below the market average of 256%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	146,139	Assets	244,220
Cost of Goods Sold	0	Liabilities	250,171
Intangible Assets	0	Expenses	255,719
Liabilities, Current	114,255	Revenues	225,110
Liabilities, Non-Current	103,574	Stockholders Equity	-5,951
Other Assets	95,600	Net Income	-59,995
Other Compr. Net Income	-62	Comprehensive Net Income	-60,026
Other Expenses	39,581	BaseVar	502,334
Other Liabilities	32,342	ECR before LimitedLiability	-30%
Other Net Income	-29,386	Economic Capital Ratio	140%
Other Revenues	225,110		
Property and Equipment	2,481		
Research and Development	97,650		
Selling, General and Administrative Expense	118,488		